98%
921
2 minutes
20
Background: Recent studies showed that clinical parameters other than cardiac function, such as physical function, cognitive function, mental status, social status, and quality of life, were associated with heart failure (HF) prognosis. These parameters have not been extensively investigated in large Japanese cohorts. Furthermore, novel biomarkers to predict prognosis or treatment responses are required to provide individualized medicine. To address these issues, we developed the Japanese Registry Of Acute Decompensated Heart Failure (JROADHF-NEXT).
Methods: JROADHF-NEXT is a prospective, multicenter, nationwide registry of patients hospitalized for acute decompensated HF. A total of 4016 patients were enrolled from 87 centers and blood and urine samples were collected from 3203 of these patients. The study protocol using the JROADHF-NEXT database was approved by all Kyushu University, International University of Health and Welfare and participating hospitals.
Results: The mean age was 72.9 ± 14.0 years and 61.4 % were male. Cardiomyopathy was the most common etiology (24.4 %). Volume overload and arrhythmia accounted for 26.3 % and 17.4 % of precipitating causes. The median follow-up period was 2.0 (1.6-2.2) years and 2-year follow-up completion rate was 88.5 % (n = 3554). The incidence rates for cardiovascular death and rehospitalization for HF were 5.2 and 16.7 per 100 person-years, respectively.
Conclusions: The JROADHF-NEXT is a large-scale HF registry comprising extensive clinical variables with a biobank. This registry is anticipated to provide valuable insights and serve as a significant source of evidence for future research and clinical practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jjcc.2025.05.015 | DOI Listing |
Cardiovasc Toxicol
September 2025
Department of Cardiac Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangdong Cardiovascular Institute, Guangzhou, 510100, Guangdong, China.
Myocardial infarction (MI), induced by ischemia and hypoxia of the coronary arteries, presents as myocardial necrosis. Patients often experience intense, prolonged retrosternal pain that is unrelieved by rest or nitrate therapy and is frequently associated with high blood myocardial enzyme levels. Physical effort may exacerbate this anxiety, increasing the likelihood of life-threatening consequences such as arrhythmias, shock, or cardiac failure.
View Article and Find Full Text PDFTrends Mol Med
September 2025
Institute of Pharmacology and Toxicology, University of Würzburg, 97078 Würzburg, Germany; Leibniz-Institut für Analytische Wissenschaften (ISAS) e.V., 44139 Dortmund, Germany. Electronic address:
Dysregulation of the RAF-MEK-ERK1/2 pathway is involved in the pathoetiology of many diseases. Its central role in cancer has led to the development of drugs targeting upstream receptors, RAS, and kinases in the extracellular signal-regulated kinase 1 (ERK1) and 2 (ERK2) signaling cascade. The use of these drugs in cancer therapy - together with ongoing monitoring of their effectiveness, evolving side-effects, and resistance mechanisms - has expanded our knowledge of both the physiological and pathological functions of ERK1/2 and could thus provide potential alternative therapeutic strategies.
View Article and Find Full Text PDFCardiovasc Revasc Med
August 2025
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. Electronic address:
Secondary mitral regurgitation (SMR) remains a prevalent and challenging complication in patients with heart failure (HF), associated with poor prognosis despite optimal guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy. Current American and European guidelines recommend GDMT as first-line therapy, with transcatheter edge-to-edge repair (TEER) reserved for severe symptomatic SMR patients who remain refractory. However, both guidelines preceded the reporting of pivotal randomized controlled trials (RESHAPE-HF2, MATTERHORN, and EFFORT) and emerging evidence in new clinical scenarios.
View Article and Find Full Text PDFInt J Cardiol
September 2025
Federico II University, Naples, Italy; Federico II University Hospital, Naples, Italy. Electronic address:
Background: Peripartum cardiomyopathy (PPCM) is a rare, life-threatening form of heart failure occurring in late pregnancy or postpartum, with variable clinical course and outcomes. We report preliminary clinical and echocardiographic findings from a national Italian registry of PPCM patients METHODS: The study was approved by the institutional Ethics Committee and registered at ClinicalTrials.gov (NCT05878041).
View Article and Find Full Text PDFJ Vasc Interv Radiol
September 2025
Chief consultant, Heart failure clinic & Echocardiography, GKNM hospital, Coimbatore, India.